Surface Oncology Inc (OQ:SURF)

Nov 25, 2020 07:00 am ET
Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief...
Nov 13, 2020 07:05 am ET
Surface Oncology Announces SRF617 and SRF388 Will Advance to Combination and Expansion Stages of Ongoing Phase 1 Clinical Trials
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both of its lead clinical programs, SRF617 (targeting CD39) and SRF388...
Nov 11, 2020 08:31 am ET
Thinking about buying stock in Surface Oncology, Northern Oil & Gas, Co-Diagnostics, Howmet Aerospace, or Aptevo Therapeutics?
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SURF, NOG, CODX, HWM, and APVO....
Nov 11, 2020 07:00 am ET
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Nov 10, 2020 06:20 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter 2020, as...
Nov 09, 2020 04:24 pm ET
Surface Oncology to Present at the Cowen IO Next Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Nov 09, 2020 09:00 am ET
Surface Oncology to Present SRF388 and SRF114 Preclinical Data at the Upcoming Society for Immunotherapy for Cancer 2020 Virtual Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388, a first in class IL-27 blocking antibody...
Oct 26, 2020 04:05 pm ET
Surface Oncology to Report SRF388 Preclinical Data at the Upcoming International Cytokine and Interferon Society’s Cytokines 2020 Virtual Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that preclinical data on SRF388, a first in class IL-27 blocking antibody...
Sep 16, 2020 05:05 pm ET
Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Sep 11, 2020 03:00 pm ET
Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Sep 09, 2020 01:15 pm ET
Surface Oncology to Present at the Baird Global Healthcare Conference
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its...
Aug 11, 2020 06:30 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2020, as...
Aug 05, 2020 11:59 am ET
Surface Oncology to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, will present at the upcoming...
May 28, 2020 04:10 pm ET
Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its 2020 Annual Meeting of Stockholders has been changed to a virtual...
May 22, 2020 09:31 am ET
Thinking about buying stock in Tetraphase Pharmaceuticals, Surface Oncology, L Brands, Tilray, or Bridgeline Digital?
NEW YORK, May 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTPH, SURF, LB, TLRY, and BLIN....
May 20, 2020 09:31 am ET
Thinking about buying stock in Surface Oncology, Inovio Pharmaceuticals, American Airlines, Altimmune, or Aurora Cannabis?
NEW YORK, May 20, 2020  InvestorsObserver issues critical PriceWatch Alerts for SURF, INO, AAL, ALT, and ACB....
May 20, 2020 07:15 am ET
Surface Oncology Fully Utilizes its $30M At-the-Market Facility
Surface Oncology  (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has raised gross proceeds of approximately $28.9 million through...
May 20, 2020 07:05 am ET
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (NYSE: MRK),...
May 15, 2020 07:30 am ET
Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced five scientific posters sharing updated preclinical data at the American...
May 14, 2020 07:30 am ET
Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity...
May 13, 2020 08:00 am ET
Surface Oncology to Present at the UBS Virtual Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that its chief executive officer, Jeff Goater, will present at the upcoming...
May 12, 2020 06:20 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter 2020, as...
Apr 23, 2020 08:00 am ET
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1 clinical trial of its first-in-class...
Mar 17, 2020 08:00 am ET
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has initiated a Phase 1/1b clinical trial of its antibody candidate...
Mar 10, 2020 06:20 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full...
Feb 25, 2020 04:05 pm ET
Surface Oncology to Present at the 40th Annual Cowen Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief...
Jan 27, 2020 04:05 pm ET
Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational...
Dec 09, 2019 05:45 pm ET
Notice to Shareholders of Surface Oncology, Inc. (NASDAQ: SURF) Regarding Dismissal of Putative Investor Class Action
This Notice, which has been authorized by the Supreme Court of the State of New York, County of New York, relates to the requested dismissal without prejudice of the putative class action captioned Ang v. Surface Oncology, Inc. et al., Index No. 655304/2019 (the “Action”).
Nov 26, 2019 08:00 am ET
Surface Oncology to Present at Evercore ISI 2nd Annual HealthCONx Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D., chief...
Nov 25, 2019 08:00 am ET
Surface Oncology Announces $25 Million Debt Financing from K2 HealthVentures
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced it has secured a debt financing facility for up to $25 million from K2...
Nov 18, 2019 06:30 am ET
Surface Oncology Announces Filing of IND for CD39 Targeted Antibody Candidate, SRF617, at Inaugural R&D Day
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has submitted an Investigational New Drug (IND) application to the...
Nov 12, 2019 06:30 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2019
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter of 2019....
Nov 07, 2019 08:00 am ET
Surface Oncology Presents Updates at the Society for Immunotherapy of Cancer’s Annual Meeting
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will present at the Society for the Immunotherapy of Cancer’s...
Oct 07, 2019 07:00 am ET
Surface Oncology to Host Analyst and Investor Day on November 18, 2019 in New York City
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company will host its inaugural Analyst and Investor Day on...
Sep 03, 2019 04:05 pm ET
Surface Oncology to Present at the Baird 2019 Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D.,...
Sep 03, 2019 07:00 am ET
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
Surface Oncology (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical oncologist currently serving as chief medical officer and vice president of clinical development at the Parker...
Aug 28, 2019 10:45 am ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ: SURF) for false and misleading SEC filings. If you...
Aug 27, 2019 08:00 am ET
Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Sunnova Energy on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ: CASA), Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ: SURF), and Sunnova Energy International, Inc. (NYSE: NOVA) on behalf...
Aug 14, 2019 08:55 pm ET
Bragar Eagel & Squire, P.C. is Investigating Casa Systems, Greenlane Holdings, Surface Oncology, and Pintec Technology on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Casa Systems, Inc. (NASDAQ: CASA), Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ: SURF), and Pintec Technology Holdings, Ltd. (NASDAQ: PT) on behalf of...
Aug 07, 2019 09:30 pm ET
Bragar Eagel & Squire, P.C. is Investigating Greenlane Holdings, Surface Oncology, and Pintec Technology on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Greenlane Holdings, Inc. (NASDAQ: GNLN), Surface Oncology, Inc. (NASDAQ: SURF), and Pintec Technology Holdings, Ltd. (NASDAQ: PT) on behalf of investors. More information about...
Aug 07, 2019 10:07 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ: SURF) for false and misleading SEC filings. If you...
Aug 07, 2019 06:05 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter of 2019....
Aug 06, 2019 05:52 pm ET
Shareholder Alert: Robbins Arroyo LLP is Investigating Surface Oncology, Inc. (SURF)
Shareholder rights law firm Robbins Arroyo LLP informs shareholders that it is investigating Surface Oncology (NASDAQ: SURF) for potential violations of federal securities laws pursuant to its April 2018 initial public offering ("IPO"). Surface Oncology completed its IPO on April 23, 2018, offering shares at $15.00. Since its IPO, Sur
Aug 06, 2019 12:55 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ:
Aug 03, 2019 11:05 am ET
Shareholder Rights Law Firm Johnson Fistel Launches Investigations
SAN DIEGO, Aug. 3, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued stock in connection with an initial public offering ("IPO"): ...
Jul 26, 2019 11:40 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Surface Oncology, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Surface Oncology, Inc. (“Surface” or “the Company”) (NASDAQ:
Jun 07, 2019 12:00 pm ET
Surface Oncology to Participate in 40th Annual Goldman Sachs Global Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will participate in the Goldman...
May 24, 2019 06:00 am ET
Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment (TME), today announced the presentation of updated preclinical findings regarding the...
May 15, 2019 04:00 pm ET
Surface Oncology to Present at Two Upcoming Healthcare Conferences
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will be participating and presenting a...
May 09, 2019 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of 2019....
Apr 24, 2019 07:00 am ET
Surface Oncology Management to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will be participating and...
Apr 01, 2019 07:00 am ET
Surface Oncology Announces Appointment of Wendy Dwyer as Chief Business Officer
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Wendy Dwyer as chief business officer. Ms. Dwyer will be...
Mar 07, 2019 04:01 pm ET
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the fourth quarter and full...
Mar 04, 2019 07:00 am ET
Surface Oncology to Present at the 39th Annual Cowen Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will provide a corporate update...
Feb 04, 2019 04:21 pm ET
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the retention of worldwide rights for its novel antibody, SRF388, targeting...
Jan 16, 2019 04:50 pm ET
Publication in ImmunoHorizons Highlights the Role of IL-27 in Upregulation of Multiple Checkpoint Proteins
Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today highlights the publication of a paper describing the biological activity of IL-27, an...
Jan 04, 2019 07:00 am ET
Surface Oncology Announces Appointment of F. Stephen Hodi, MD to its Scientific Advisory Board
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of the F. Stephen Hodi, MD to the company’s scientific...
Dec 21, 2018 07:00 am ET
Surface Oncology Added to the NASDAQ Biotechnology Index
Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI)....
Dec 18, 2018 04:01 pm ET
Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today updates related to its product pipeline, notably the significant reduction...
Dec 17, 2018 07:00 am ET
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning the promotion of Jessica Fees to senior vice president, finance and...
Nov 20, 2018 07:00 am ET
Surface Oncology Announces Upcoming Investor Presentations
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced this morning that it will host presentations at two investor conferences in the...
Nov 13, 2018 06:30 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the third quarter of 2018....
Aug 30, 2018 09:59 am ET
Surface Oncology to Present at the Baird 2018 Global Healthcare Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vito Palombella, Ph.D.,...
Aug 14, 2018 07:00 am ET
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter of 2018....
Jul 30, 2018 02:24 pm ET
FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma
Surface Oncology (NASDAQ: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Jun 21, 2018 07:00 am ET
Surface Oncology Recognized as one of the “Best Places to Work” by Boston Business Journal
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it has been recognized as one of the Best Places to Work in 2018 by the...
Jun 12, 2018 07:00 am ET
Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the initiation of a Phase I trial of SRF373, a fully human antibody...
Jun 11, 2018 05:07 pm ET
Surface Oncology to be Added to the Russell 3000 Index and Russell 2000 Index
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that it will join the small-cap Russell 2000 index at the conclusion of the...
Jun 08, 2018 07:10 am ET
Surface Oncology to Present at Goldman Sachs 39th Annual Global Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present at the Goldman Sachs...
May 29, 2018 05:00 pm ET
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2018
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of 2018....
May 15, 2018 04:01 pm ET
Surface Oncology to Present at 2018 UBS Global Healthcare Conference
Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present a company overview at...
Apr 23, 2018 04:30 pm ET
Surface Oncology Announces Closing of $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement
CAMBRIDGE, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (“Surface”), an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the closing of its initial public offering of 7,200,000 shares of common...
Apr 18, 2018 09:00 pm ET
Surface Oncology Announces $119.5 Million Aggregate Financing, Consisting of $108.0 Million Initial Public Offering and $11.5 Million Concurrent Private Placement
CAMBRIDGE, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (“Surface”) (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment, today announced the pricing of its initial public offering of 7,200,000 shares...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.